1 Introduction Glioblastoma (GBM, WHO grade IV) is the most aggressive form of primary brain tumor, with a median survival of 14–17 months in affected patients [1-3]. Temozolomide (TMZ) secured approval for GBM treatment on the basis of evidence derived from a randomized phase III clinical trial [4]. Despite the rapid emergence of TMZ resistance in the majority of GBM patients, this agent remains the first-line chemotherapeutic of choice for the disease [5].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile